Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture

Journal of Neuroscience Research

Volumn 70, Issue 6, 2002, Pages 766-773

  Antonelli, T ^a   Tomasini, M C ^a   Finetti, S ^a   Giardino, L ^b   Calza L ^b   Fuxe, K ^c   Soubrie P ^d   Tanganelli, Sergio ^a   Ferraro, L ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SANOFI   (France)

Author keywords

Dopamine uptake; Neurodegenerative disorders; Neurotensin receptor antagonist; Tyrosine hydroxylase immunoreactivity

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CALPHOSTIN C; GLUTAMIC ACID; NEUROTENSIN; NEUROTENSIN RECEPTOR ANTAGONIST; PEPTIDE; PROTEIN KINASE C INHIBITOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; EMBRYO; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; MESENCEPHALON; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; DOPAMINE; EMBRYO; ENZYME INHIBITORS; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NAPHTHALENES; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTENSIN; PYRAZOLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; TYROSINE 3-MONOOXYGENASE;

EID: 0037114682     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10415     Document Type: Article

References (53)

1. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D. 2001. Immunoistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes. Neuroscience 105:509-520.
2. Baldino F Jr, Wolfson B. 1985. Postsynaptic actions of neurotensin on preoptic-anterior hypothalamic neurons in vitro. Brain Res 325:161-170.
3. Berger B, Di Porzio U, Daguet MC, Gay M, Vigny A, Glowinski J, Prochiantz A. 1982. Long-term development of mesencephalic dopaminergic neurons of mouse embryos in dissociated primary cultures: Morphological and histochemical characteristics. Neuroscience 7:193-205.
4. Blandini F, Greenamyre JT. 1998. Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fund Clin Pharmacol 12:4-12.
5. Blandini F, Porter RH, Greenamyre JT. 1996. Glutamate and Parkinson's disease. Mol Neurobiol 12:73-94.
6. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, Mahalik TJ. 1996. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 111:1-7.
7. Brouard A, Pelaprat D, Dana C, Vial M, Lhiaubet AM, Rostene W. 1992. Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J Neurosci 12:1409-1415.
8. 3H]dopamine release from rat mesencephalic cells in primary culture. J Neurochem 62:1416-1425.
9. 3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: Evidence from a receptor autoradiographic study. Brain Res 564:37-44.
10. Carraway R, Leeman SE. 1973. The isolation of new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861.
11. Cathala L, Paupardin-Tritsch D. 1997. Neurotensin inhibition of the hyperpolarization-activated cation current (1h) in the rat substantia nigra pars compacta implicates the protein kinase C pathway. J Physiol 503:87-97.
12. Chase TN, Oh JD, Blanchet PJ. 1998. Neostriatal mechanisms in Parkinson's disease. Neurology 51:S30-S35.
13. Chinaglia G, Probst A, Palacios JM. 1990. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study in basal ganglia. Neuroscience 39:351-360.
14. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
15. Christoffersen CL, Meltzer LT. 1995. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: Possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 67:373-381.
16. Deutch AY, Zahm DS. 1992. The current status of neurotensin-dopamine interactions. Issues and speculations. Ann N Y Acad Sci 668:232-252.
17. Doble A. 1999. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther 81:163-221.
18. Faggin BM, Cubeddu LX. 1990. Rapid desensitisation of dopamine release induced by neurotensin and neurotensin fragments. J Pharmacol Exp Ther 253:812-818.
19. Fernandez A, Jenner P, Marsden CD, De Ceballos ML. 1995. Characterization of neurotensin-like immunoreactivity in human basal ganglia: Increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides 16:339-346.
20. Fernandez A, de Ceballos ML, Rose S, Jenner P, Marsden CD. 1996. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 3:823-830.
21. Ferraro L, Tanganelli, S. O'Connor WT, Bianchi C, Ungerstedt U, Fuxe, K. 1995. Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. Synapse 20:362-364.
22. Ferraro L, Antonelli T, O'Connor WT, Fuxe K, Soubrié P, Tanganelli S. 1998. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: Functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J Neurosci 18:6977-6989.
23. Ferraro L, Tomasini MC, Siniscalchi A, Fuxe K, Tanganelli S, Antonelli T. 2000. Neurotensin increases endogenous glutamate release in rat cortical slices. Life Sci 66:927-936.
24. Ferraro L, Tomasini MC, Fernandez M, Bebe BW, O'Connor WT, Fuxe K, Glennon JC, Tanganelli S, Antonelli T. 2001. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: A dual-probe microdialysis study in intact conscious rat brain. Neuroscience 102:113-120.
25. Fuxe K, O'Connor WT, Antonelli T, Osborne PG, Tanganelli S, Agnati LF, Ungerstedt U. 1992. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc Natl Acad Sci USA 89:5591-5595.
26. Gully D, Canton M, Boigegrain K, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A. 1993. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 90:65-69.
27. 3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices. Neuropeptides 32:465-471.
28. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. 1989. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159:548-553.
29. Kulinska-Niedziela I, Paluszak J. 1997. Neurotensin - Structure, origin and biological function. Postepy Hig Med Dosw 51:329-342.
30. Mateu G, Privat A, Thibault J, Vignon, J. 2000. Modulation of glutamate neurotoxicity on mesencephalic dopaminergic neurons in primary cultures by the presence of striatal target cells. Int J Dev Neurosci 18:607-613.
31. Meldrum, B, Garthwaite J. 1990. Excitatory aminoacid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11:379-387.
32. Meltzer LT, Christoffersen CL, Serpa KA. 1997. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev 21:511-518.
33. 3H]dopamine release from dissociated cell cultures of rat ventral mesencephalon. J Neurochem 52:1300-1310.
34. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, Yamaguchi S, Kawabata S, Okada M. 1998. Glutamate receptors: Brain function and signal transduction. Brain Res Rev 26:230-235.
35. Nalivaiko E, Michaud JC, Soubrié P, Le Fur G. 1998. Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons. Neuroscience 86:799-811.
36. Nemeroff CB, Cain ST. 1985. Neurotensin-dopamine interactions in the CNS. Trends Pharmacol Sci 6:201-205.
37. Nouel D, Faure MP, St Pierre JA, Alonso R, Quirion R, Beaudet A. 1997. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. J Neurosci 17:1795-1803.
38. Ozawa S, Kamiya H, Tsuzuki K. 1998. Glutamate receptors in the mammalian central nervous system, Neurobiol 54:581-618.
39. Palacios JM, Kuhar MJ. 1981. Neurotensin receptors are located on dopamine-containing neurones in rat midbrain. Nature 294:587-589.
40. Prochiantz A, di Porzio U, Kato A, Berger B, Glowinski J. 1979. In vitro maturation of mesencephalic dopaminergic neurons from mouse embryos is enhanced in presence of their striatal target cells. Proc Natl Acad Sci USA 76:5387-5391.
41. Rostène W, Brouard A, Dana C, Masuo Y, Agid F, Vial M, Lhiaubet AM, Pelaprat D. 1992. Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence. Ann N Y Acad Sci 668:217-231.
42. Saleh TM. 1997. Visceral afferent stimulation-evoked changes in the release of peptides into the parabrachial nucleus in vivo. Brain Res 778:56-63.
43. Sanz B, Exposito I, Mora F. 1993. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport 4:1194-1196.
44. Schimpff RM, Avard C, Fenelon G, Lhiaubet AM, Tenneze L, Vidailhet M, Rostene W. 2001. Increased plasma neurotensin concentrations in patients with Parkinson's disease. J Neurol Neurosurg Psychiatr 70:784-786.
45. Skaper SD, Facci L, Strijbos PJ. 2001. Neuronal protein kinase signaling cascades and excitotoxic cell death. Ann N Y Acad Sci 939:11-22.
46. Sonsalla PK, Albers DS, Zeevalk GD. 1998. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14:69-74.
47. Sotty F, Souliere F, Brun P, Chouvet G, Steinberg R, Soubrie P, Renaud B, Suaud-Chagny MF. 1998. Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: A combined in vivo electrochemical and electrophysiological study. Neuroscience 85:1173-1182.
48. Tanji H, Araki T, Fujihara K, Nagasawa H, Itoyama Y. 1999. Alteration of neurotensin receptors in MPTP-treated mice. Peptides 20:803-807.
49. 3H]GABA release from cerebral cortical cultures: An in vitro approach for studying glutamate-induced neurotoxicity. Synapse 30:247-254.
50. Trudeau LE. 2000. Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: Evidence for the involvement of multiple receptors. Neuroscience 97:293-302.
51. Vincent JP, Mazella J, Kitabgi P. 1999. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20:302-309.
52. Yamada M, Richelson E. 1995. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain. Neuroscience 64:405-417.
53. Yung KK. 1998. Localization of ionotropic and metabotropic glutamate receptors in distinct neuronal elements of the rat substantia nigra. Neurochem Int 33:313-326.